Crystal Genomics to start P2 trial of Covid-19 treatment

Crystal Genomics said that the Ministry of Food and Drug Safety has given the go-ahead for conducting its phase 2 clinical trial of Camostat, a serine hydrolase inhibitor, for treating Covid-19. The trial aims to evaluate the safety and efficacy of the drug by carrying out the trial on 100 patients with mild and moderate Covid-19 symptoms. After completing enrollment, the company will divide the patients into two groups and administer either Camostat or placebo for a week. KoreaBioMedicalReviw